INNIO Technology Selected for First 100% Hydrogen Engine Power Plant in Asia Pacific
19.11.2021 09:00:00 EET | Business Wire | Press release
INNIO today announced that Hyosung Heavy Industries (Hyosung) has selected INNIO Jenbacher ‘Ready for Hydrogen’ engine technology for the first pilot power plant project in APAC that will be fueled by 100% hydrogen. The pilot hydrogen power plant will be built at the Hyosung Chemical Yongyeon Plant in Ulsan, South Korea, setting a benchmark by becoming the first 100% hydrogen power plant to be operated in the region. It will run on hydrogen produced as a byproduct at the chemical plant that is normally sold off to an industrial gas company. The project is expected to achieve commercial operation in 3Q 2022 and complete the demonstration by end of 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211118006247/en/
Park Jeong-Ha, General Manager at Hyosung (Photo: Business Wire)
“INNIO has based its strategy on hydrogen becoming a driver of the energy transition, as it is uniquely positioned to shape a low- through no-carbon energy sector. INNIO launched its ‘Ready for Hydrogen’ portfolio to meet customers’ demands for sustainable solutions, such as at Hyosung, to establish hydrogen-based power generation. We are pleased to be their hydrogen engine technology partner of choice and to establish the first 100% hydrogen power plant in APAC,” said Olaf Berlien, president and CEO of INNIO. “We will continue our relentless focus to deliver INNIO technologies and services that will help our customers to reduce their carbon footprint down to zero.”
“Hyosung is striving to improve its impact on climate change by embracing the global energy transition. We have joined forces with INNIO to support our efforts to reduce carbon emissions while exploring commercial and sustainable opportunities related with our hydrogen byproduct production,” commented Park Jeong-Ha, General Manager at Hyosung. “Our climate change response strategies have set the goal of reducing emissions and energy consumption while increasing energy efficiency. INNIO Jenbacher provides the efficient and proven technology that helps us meet this goal.”
As a shaper of a low-carbon economy, INNIO is preparing for a secure, affordable, and climate-neutral energy future for everyone. The pilot power plant using INNIO Jenbacher technology, will be the second power plant in the 1-MW range that can be fueled with 100% hydrogen. INNIO is a hydrogen pioneer for more than 20 years, when the first Jenbacher 150-kilowatt pilot engine ran on 100 percent hydrogen at a demonstration plant in northern Germany. Two decades later, in 2020, after a number of additional demonstration projects, INNIO and HanseWerk Natur demonstrated the world’s first hydrogen engine using variable hydrogen and natural gas mixtures up to 100% hydrogen on an INNIO Jenbacher engine. The collaboration with Hyosung now marks a further milestone for INNIO to help drive the energy transition.
About INNIO
INNIO is a leading provider of renewable gas and hydrogen-rich solutions and services for power generation and compression at or near the point of use. With our Jenbacher and Waukesha products, INNIO helps to provide communities, industry and the public access to sustainable, reliable and economical power ranging from 200 kW to 10 MW. We also provide life-cycle support and digital solutions to the more than 53,000 delivered gas engines globally, through our service network in more than 100 countries. We deliver innovative technology driven by sustainability, decentralization, and digitalization to help lead the way to a greener future. Headquartered in Jenbach, Austria, the business also has primary operations in Welland, Ontario, Canada, and Waukesha, Wisconsin, U.S. For more information, visit the company's website at www.innio.com. Follow INNIO on Twitter and LinkedIn .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211118006247/en/
Contact information
Susanne Reichelt
INNIO
+43 664 80833 2382
susanne.reichelt@innio.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FlexTrade Expands Portfolio Risk and Analytics Capabilities Through Strategic Partnership with Portx13.7.2026 16:30:00 EEST | Press release
FlexTrade Systems (@FlexTrade), a global leader in multi-asset execution and order management systems, and Portx, an advanced portfolio construction and analytics provider, today announced the integration of Portx’sreal-time portfolio construction, optimization, and risk analytics capabilities into FlexTrade’s integrated buy-side order and execution management system (OEMS), FlexONE. The partnership comes as buy-side firms place greater emphasis on real-time risk management across increasingly complex portfolios, advanced hedging strategies, and supporting operating models. For hedge funds and institutional asset managers, particularly those running multi-strategy or multi-asset approaches, the ability to assess portfolio risk, review pro forma exposures, and act on those insights within the order and execution management workflow is becoming increasingly important. FlexTrade's integration with Portx builds on FlexONE's existing real-time front-office risk analytics capabilities, inclu
Xsolla Connect Returns to Brighton13.7.2026 16:22:00 EEST | Press release
Xsolla, a global video game commerce company, today announced the launch of an exclusive networking event for the UK game development community, Xsolla Connect, taking place with Develop:Brighton 2026 on July 15, 2026. Designed to bring together independent and mid-tier developers, publishers, investors, and industry professionals, the event will offer a focused evening of meaningful connections and actionable insights at one of the UK’s most important annual games gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713748542/en/ Graphic: Xsolla Develop:Brighton has long served as a cornerstone of the European video games industry, drawing developers, publishers, investors, and studio leaders from across the UK and beyond to share knowledge, explore opportunities, and forge lasting business relationships. Xsolla’s event will build on that momentum by providing attendees with a dedicated space to connect with peers
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom